Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Alberto Cruz‐Bermúdez(Hospital Universitario Puerta de Hierro Majadahonda), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 140
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
|Circulation|2019|344
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
|Free Radical Biology and Medicine|2019|215
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
|Translational Lung Cancer Research|2022|19